Dyadic International (NASDAQ:DYAI) Issues Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Dyadic International (NASDAQ:DYAI) announced its earnings results on Wednesday. The biotechnology company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.03), FiscalAI reports. Dyadic International had a negative return on equity of 537.31% and a negative net margin of 221.09%.The business had revenue of $0.57 million during the quarter, compared to the consensus estimate of $1.34 million.

Dyadic International Price Performance

NASDAQ:DYAI traded up $0.03 during midday trading on Wednesday, hitting $0.87. The company had a trading volume of 100,793 shares, compared to its average volume of 60,100. The company has a market capitalization of $31.58 million, a PE ratio of -3.64 and a beta of 1.29. The company has a quick ratio of 2.85, a current ratio of 2.85 and a debt-to-equity ratio of 1.92. Dyadic International has a 52-week low of $0.71 and a 52-week high of $1.45. The stock’s fifty day moving average price is $0.83 and its 200-day moving average price is $0.95.

Institutional Investors Weigh In On Dyadic International

Hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its holdings in shares of Dyadic International by 16,146.7% in the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 26,965 shares in the last quarter. Landscape Capital Management L.L.C. purchased a new position in shares of Dyadic International during the 3rd quarter valued at about $190,000. Finally, Geode Capital Management LLC lifted its position in Dyadic International by 13.7% in the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after buying an additional 36,266 shares during the last quarter. Institutional investors own 27.95% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Dyadic International in a report on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $3.00.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.